Two-Year Neurodevelopmental Outcomes of Ventilated Preterm Infants Treated with Inhaled Nitric Oxide

Case Western Reserve University, Cleveland, OH, USA.
The Journal of pediatrics (Impact Factor: 3.79). 02/2010; 156(4):556-61.e1. DOI: 10.1016/j.jpeds.2009.10.011
Source: PubMed


In a randomized multi-center trial, we demonstrated that inhaled nitric oxide begun between 7 and 21 days and given for 24 days significantly increased survival without bronchopulmonary dysplasia (BPD) in ventilated premature infants weighing <1250 g. Because some preventative BPD treatments are associated with neurodevelopmental impairment, we designed a follow-up study to assess the safety of nitric oxide.
Our hypothesis was that inhaled nitric oxide would not increase neurodevelopmental impairment compared with placebo. We prospectively evaluated neurodevelopmental and growth outcomes at 24 months postmenstrual age in 477 of 535 surviving infants (89%) enrolled in the trial.
In the treated group, 109 of 243 children (45%) had neurodevelopmental impairment (moderate or severe cerebral palsy, bilateral blindness, bilateral hearing loss, or score <70 on the Bayley Scales II), compared with 114 of 234 (49%) in the placebo group (relative risk, 0.92; 95% CI, 0.75-1.12; P = .39). No differences on any subcomponent of neurodevelopmental impairment or growth variables were found between inhaled nitric oxide or placebo.
Inhaled nitric oxide improved survival free of BPD, with no adverse neurodevelopmental effects at 2 years of age.

Download full-text


Available from: Avital Cnaan,
  • Source
    • "There was a concomitant decrease in the duration of assisted ventilation and pulmonary morbidity at 1 y in these infants (8,9). BPD is of multifactorial origin, however, and substantial morbidity remains even after iNO treatment (8,10). There is therefore a need for new therapeutic approaches and combination therapies to prevent the disorder. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background: Surfactant dysfunction may contribute to the development of bronchopulmonary dysplasia (BPD) in persistently ventilated preterm infants. We conducted a multicenter randomized, blinded, pilot study to assess the safety and efficacy of late administration of doses of a surfactant protein-B (SP-B)-containing surfactant (calfactant) in combination with prolonged inhaled nitric oxide (iNO) in infants ≤1,000 g birth weight (BW). Methods: We randomized 85 preterm infants ventilated at 7–14 d after birth to receive either late administration of surfactant (up to 5 doses) plus prolonged iNO or iNO alone. Large aggregate surfactant was isolated from daily tracheal aspirates (TAs) for measurement of SP-B content, total protein, and phospholipid (PL). Results: Late administration of surfactant had minimal acute adverse effects. Clinical status as well as surfactant recovery and SP-B content in tracheal aspirate were transiently improved as compared to the controls; these effects waned after 1 d. The change in SP-B content with surfactant dosing was positively correlated with SP-B levels during treatment (r = 0.50, P = 0.02). Conclusion: Low SP-B values increased with calfactant administration, but the relationship of this response to SP-B levels suggests that degradation is a contributing mechanism for SP-B deficiency and surfactant dysfunction. We conclude that late therapy with surfactant in combination with iNO is safe and transiently increases surfactant SP-B content, possibly leading to improved short- and long-term respiratory outcomes.
    Pediatric Research 10/2012; 72(6). DOI:10.1038/pr.2012.136 · 2.31 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The authors designed, fabricated, and tested a four-channel, analog-ternary charge-coupled device (CCD) correlator that extends the state of the art in several important areas. In addition to a sampling rate up to 40 Ms/s, dynamic range of 66 dB, and nonlinearity below -50 dB, the device exhibits a level of integration and user-friendliness not previously available. The correlator is intended for use in communications and radar systems where pseudonoise codes are used
    Custom Integrated Circuits Conference, 1989., Proceedings of the IEEE 1989; 06/1989
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background: This section is under preparation and will be included in the next issue. Objectives: To determine whether, in preterm newborn infants who have hypoxic respiratory failure, treatment with inhaled nitric oxide improves oxygenation and reduces the rates of death, or adverse neurodevelopmental outcome. Search strategy: Electronic and hand searching of pediatric/neonatal literature and personal data files. Selection criteria: Randomized and quasi randomized studies in preterm infants with hypoxic respiratory failure. Administration of inhaled nitric oxide. Clinically relevant outcomes, including death, oxygenation, intraventricular haemorrhage. Data collection and analysis: One randomized controlled trial of nitric oxide therapy was found in preterm infants with a high risk of developing bronchopulmonary dysplasia (Subhedar 1997). Main results: No significant effect of inhaled nitric oxide on any outcome variable was found. In particular there was no effect on the primary outcome variable of death or bronchopulmonary dysplasia. Reviewer's conclusions: There is currently no published information to support the use of inhaled nitric oxide in preterm infants. Preterm infants should not be treated with inhaled nitric oxide except in the context of prospective, randomized controlled trials.
    Cochrane database of systematic reviews (Online) 12/2010; 12(12):CD000509. DOI:10.1002/14651858.CD000509.pub4 · 6.03 Impact Factor
Show more